Australian researchers have discovered a previously overlooked group of bladder nerves that help detect urinary tract ...
Cyclooxygenase-2 is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer. Cyclooxygenase-2 is overexpressed in bladder cancer cells ...
Concurrent chemoradiotherapy (CRT) for bladder cancer: Practice patterns and outcomes in the general population. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract ...
In a phase 1b-2 trial, neoadjuvant disitamab vedotin plus tislelizumab shows preliminary efficacy and acceptable toxicity in HER2-expressing muscle-invasive bladder cancer -- and may enable ...
Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, with around half of patients affected. Prognostic tests can help identify patients ...
Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.
Anticancer effects of polyadenylic-polyuridylic acid (poly[A:U]) and uncoupling of chemokine receptor signaling: Role of CCR5 and CXCR3 No significant financial relationships to disclose. This is an ...
The phase 2 DESTINY-PanTumor02 trial included patients with HER2-expressing solid tumors such as bladder, pancreatic and rare tumors. Findings from an analysis of a phase 2 trial demonstrated that ...
Cyclooxygenase-2 is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer. The effects of TKIs on bladder cancer in vivo were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results